- Policy
- Evaluation different after Kymriah·Zolgensma benefits?
- by Lee, Tak-Sun Jul 7, 2023 05:43am
- The ultra-expensive treatments Zolgensma and Kymriah are supposed to go through a performance evaluation, but whether or not they are disclosed is different. As a pre-approved drug, Zolgensma, which is subject to review by an expert review committee, has performance evaluation results disclosed to the public, whereas Kymriah does not. Therefore,
- Policy
- Pres. Yoon urges swift legislation for remote treatment
- by Kang, Shin-Kook Jul 6, 2023 05:39am
- President Yoon Suk-yeol has instructed the Ministry of Health and Welfare to make every effort to pass the amendment of the Medical Service Act for the introduction of non-face-to-face treatment, which is currently under discussion in the National Assembly, raising hopes for its rapid legislation. President Yoon made these remarks on the 4th
- Company
- Vabysmo’s real-world data to hold leader Eylea in check
- by Jung, Sae-Im Jul 6, 2023 05:39am
- The competition between the current lead ‘Eylea’ and the new drug ‘Vabysmo’ is fierce in the macular degeneration treatment market. Based on the real-world data that demonstrated Vabysmo’s consistent effect on patients who switched from Eylea, the company built evidence for patients to switch to Vabysmo. To defend the lead, Eylea’s co
- Policy
- Roche Korea, "No decision has been made to resupply Madopar
- by Lee, Tak-Sun Jul 6, 2023 05:39am
- Roche Korea recently announced that it has no plans to resupply Madopar, a Parkinson's disease treatment for which the grace period for the deletion of benefits was recently extended. It is explained that the headquarters did not make a decision to resupply, and that no agreement was signed with any organization for resupply. The extension of
- Company
- Industry anxiously awaits reimb of SGLT-2 inhibitors
- by Jung, Sae-Im Jul 6, 2023 05:39am
- The reimbursement applications that companies of SGLT-2 inhibitors filed to receive reimbursement for their heart failure indication are expected to undergo a difficult journey. The largest barrier to their reimbursement is the concern over the enormous amount of fiscal spending the drugs will bring due to the broad target patient group.
- Company
- Sidapvia, a combination of Forxiga in collaboration
- by Jung, Sae-Im Jul 6, 2023 05:38am
- AstraZeneca Korea announced on the 5th that it has obtained permission from the Ministry of Food and Drug Safety for the Forxiga combination 'Sidapvia (Dapagliflozin 10mg + Sitagliptin 100mg)'. Sidapvia, approved as a treatment for type 2 diabetes, is a combination drug that combines the SGLT-2 inhibitor Dapagliflozin's original product Forx
- Company
- Dongkook and GC agree to co-promote Glarzia in Korea
- by Kim, Jin-Gu Jul 5, 2023 05:45am
- On the 3rd, Dongkook Pharmaceutical and GC Biopharma announced that the two companies have signed a business agreement for the domestic sales and marketing of ‘Glarzia Prefilled Pen (insulin glargine),’ a biosimilar of the insulin injection Lantus. Glarzia is a Lantus biosimilar developed by the Indian biosimilar pharmaceutical company
- Policy
- Will AZ/Kolon succeed in challenging COPD combi benefit?
- by Lee, Tak-Sun Jul 5, 2023 05:45am
- Two COPD 3 drugs combi inhalers that are competing for reimbursement are not easily able to get out of the HIRA stage. AstraZeneca's 'Breztri Aerosphere' also requested a re-evaluation of the committee's results, while Kolon Pharmaceutical's 'Trimbow Inhaler' took on a re-challenge for reimbursement despite the drug evaluation committee's con
- Policy
- AZ Capivasertib, designated GIFT No. 8
- by Lee, Hye-Kyung Jul 5, 2023 05:45am
- On the 4th, the Ministry of Food and Drug Safety designated AstraZeneca Korea's breast cancer treatment Capivasertib as the 8th "Global Innovation Product Rapid Review (GIFT)." Starting with Lunsumio, a lymphoma treatment in Roche Korea, which was designated as GIFT No. 1 in November last year, it has been designated up to No. 8 recently, but no
- Opinion
- [Reporter’s View]Kudos to Keytruda for filing 13 reimb apps
- by Eo, Yun-Ho Jul 5, 2023 05:45am
- A truly extraordinary case has emerged. MSD Korea has applied for the reimbursement of 13 Keytruda indications at once. This is an unprecedented event, the first time such a large amount of applications had been filed for a single drug since the positive list system was implemented for drug reimbursement in Korea. After submitting the ap
